Investors Presentation Q2 FY 27.

November 10, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400051. Scrip Code: 524774 Symbol: NGLFINE Dear Sir/Madam, Sub: Investor Presentation – Q2FY 27. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Investor Presentation – Q2FY 27. The above presentation is also being made available on the Company’s website at www.nglfinechem.com. You are requested to kindly take the information on record. Thanking you, Yours faithfully, For NGL Fine-Chem Limited Shivam Gharat Company Secretary and Compliance Officer M. No.: A56704 Encl: As Above. NGL Fine-Chem Limited I N V E S T O R P R E S E N T A T I O N Q2 FY 27 Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of NGL Fine-Chem Limited, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. NGL Fine-Chem Limited may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. 02 NGL Fine-Chem Limited Inside Pg. No. Pg. No. This Presentation 04 10 Q2FY27 Overview, Highlights Key Strengths and Strategy Pg. No. Historical Financial Performance Q2FY27 Highlights 05 MANAGEMENT COMMENTARY 06 QUARTERLY OPERATIONAL METRICS 07 SUMMARY OF PROFIT AND LOSS STATEMENT 08 SUMMARY OF BALANCE SHEET 09 SUMMARY OF CASH FLOW STATEMENT MANAGEMENT COMMENTARY Dear Shareholders, “Q2FY27 was a strong quarter, marked by robust In the near term, the new capacity will serve demand across our product segments and unregulated markets, which gives us ample geographies. Revenue growth was led by volumes, headroom for growth there. At the same time, we and our first-half performance keeps us firmly on are steadily building the plant’s regulatory track with the guidance we shared earlier in the credentials. We have begun transferring our year. European registrations to the new facility and expect to complete the process by the end of 2027. During the quarter, we commissioned Phase II on the timeline we had communicated, and the facility In the US, we have filed Veterinary Master Files for is now fully staffed. With the plant on stream, its nine products, and our customer is expected to Rahul Nachane operating costs, including employee expenses, complete its filings by December 2026, which will interest and depreciation, will begin to flow through pave the way for a USFDA inspection of the facility. MANAGING DIRECTOR the P&L. This is likely to weigh on margins over the We remain positive about our growth trajectory. The next few quarters as utilisation builds up, which we coming quarters will reflect the cost of ramping up expect to reach 30% to 40% over the next two to the new plant, but with sustained demand, three quarters. Absolute profits, however, should expanded capacity and a widening regulatory continue to rise as volumes from the new plant footprint, we believe the business is well placed to scale up. We are reasonably confident of improved deliver profitable growth over the medium term.” profitability at the consolidated level once the plant reaches optimum utilisation. 05 NGL Fine-Chem Limited Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q2FY26 Q1FY27 Q2FY27 PARTICULARS Q2FY26 Q1FY27 Q2FY27 ANIMAL API 90% 95% 95% TOP 3 PRODUCTS 32% 31% 29% HUMAN API 4% 3% 3% TOP 5 PRODUCTS 46% 48% 43% INTERMEDIATES 5% 1% 1% TOP 10 PRODUCTS 69% 68% 65% FORMULATIONS 1% 0% 0% GEOGRAPHIC MIX CUSTOMER CONCENTRATION PARTICULARS Q2FY26 Q1FY27 Q2FY27 PARTICULARS Q2FY26 Q1FY27 Q2FY27 Asia 40% 40% 41% TOP 3 CUSTOMERS 11% 18% 11% Europe 10% 10% 9% TOP 5 CUSTOMERS 16% 26% 16% India 29% 20% 22% ROW 21% 30% 28% TOP 10 CUSTOMERS 26% 38% 26% USA 0% 0% 0% 06 NGL Fine-Chem Limited Summary of Profit and Loss Statement ₹ IN CRORES PARTICULARS Q2FY26 Q1FY27 Q2FY27 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 120.26 139.16 158.71 14.05% 31.97% OTHER INCOME 2.05 7.43 1.20 -83.85% -41.46% TOTAL INCOME 122.31 146.59 159.91 9.09% 30.74% TOTAL OPERATING EXPENSES 103.10 115.88 130.64 12.74% 26.71% EBITDA 17.16 23.29 28.06 20.48% 63.52% EBITDA MARGIN (%) 14.27% 16.73% 17.68% 94 bps 341 bps FINANCE COST 1.16 0.99 1.12 13.13% -3.45% DEPRECIATION AND AMORTISATION EXPENSES 5.09 5.25 6.55 24.76% 28.68% PROFIT BEFORE TAX 12.96 24.48 21.60 -11.76% 66.67% PROFIT AFTER TAX 9.63 18.40 16.25 -11.68% 68.74% 07 NGL Fine-Chem Limited Summary of Balance Sheet ₹ IN CRORES PARTICULARS FY26 H1FY27 SHAREHOLDERS FUND 329.23 362.61 NON CURRENT LIABILITIES 66.25 67.50 LONG TERM BORROWINGS 56.40 50.68 CURRENT LIABILITIES 150.01 197.64 SHORT TERM BORROWINGS 52.02 71.43 TOTAL EQUITY AND LIABILITIES 545.50 627.75 NON CURRENT ASSETS 269.11 304.49 NET BLOCK 164.09 285.70 CURRENT ASSETS 276.39 323.26 INVENTORIES 70.28 118.38 TRADE RECEIVABLES 130.88 136.76 CASH & BANK BALANCES 5.11 5.59 TOTAL ASSETS 545.50 627.75 08 NGL Fine-Chem Limited Summary of Cash Flow Statement ₹ IN CRORES PARTICULARS FY26 H1FY27 CASH FLOW FROM OPERATING ACTIVITIES 43.32 35.80 CASH FLOW FROM INVESTING ACTIVITIES (70.59) (44.05) CASH FLOW FROM FINANCING ACTIVITIES 29.55 10.50 NET CASH FLOW 2.27 2.24 CASH AT THE BEGINNING OF YEAR 0.53 2.81 CASH AT THE END OF YEAR 2.81 5.05 09 NGL Fine-Chem Limited Overview, Strengths and Strategy 11 LEADING ANIMAL HEALTH COMPANY 12 LEADERSHIP IN VETERINARY API SEGMENT 13 STATE-OF-THE-ART MANUFACTURING CAPABILITIES 14 STRATEGY FOR NEXT LEG OF GROWTH Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human APIs), our top products manufacturing across the globe with 1 Intermediates and facilities country-wise • Reliable supplier 11 finished dosage • Growing position in regulatory approvals focused on good forms next 4 – taking market • Strong R&D sale support to all share from other capabilities in • Strong presence in customers • Best quality and players custom synthesis unregulated markets value-driven pricing 11 NGL Fine-Chem Limited Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT API SEGMENT 13 CONCENTRATION Strong controls of processes with (₹ IN CRORES) (OF SALES FY26) 95% in-house manufacturing and CAGR backward integrated facilities leading to cost competitiveness FY26 466 CUSTOMER PRODUCT FY25 327 FY24 300 TOP 3 10% 28% High quality and [Showing first 8,000 characters — download PDF for full document]